Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

A subset of non-small cell lung cancer (NSCLC) tumors (5%) harbors an anaplastic lymphoma kinase (ALK) translocation that drives tumorigenesis. The clinically approved first-line treatment crizotinib specifically inhibits ALK and improves progression-free survival (PFS) in treated and untreated pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Muller, Ittai B, de Langen, Adrianus J, Giovannetti, Elisa, Peters, Godefridus J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602476/
https://www.ncbi.nlm.nih.gov/pubmed/28979145
http://dx.doi.org/10.2147/OTT.S109493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602476/
https://www.ncbi.nlm.nih.gov/pubmed/28979145
http://dx.doi.org/10.2147/OTT.S109493

Ejemplares similares